Novartis exercises option to acquire IFM Due for $835m

The acquisition will enhance Novartis’ portfolio in inflammation-driven diseases.

Vishnu Priyan March 14 2024

Novartis has exercised an option for the acquisition of all outstanding capital stock of IFM Therapeutics subsidiary IFM Due for $835m.

The strategic acquisition will grant Novartis the complete rights to IFM Due’s portfolio of STING antagonists, which address a range of serious inflammation-driven diseases.

IFM Due, established in February 2019, develops small molecule orally available drug candidates targeting the cyclic GMP-AMP synthase, a stimulator of the interferon genes (cGAS-STING) pathway, which is implicated in several serious diseases.

The collaboration between IFM Due and Novartis began in September 2019 when the companies made an option and partnership agreement.

Novartis agreed to fund research and development by IFM Due for the cGAS-STING programme in exchange for an option to acquire the company.

With the option exercised, IFM received an upfront payment of $90m from Novartis and is also entitled to milestone payments of $745m.

The acquisition is a significant move for Novartis, as it will secure complete rights for IFM Due’s portfolio comprising STING antagonists.

These assets have the potential to treat serious inflammation-driven ailments characterised by excessive interferon and other pro-inflammatory cytokine signalling.

The cGAS-STING pathway functions within the innate immune system to sense cytosolic DNA, a signal of cellular danger, and then triggers a STING-dependent inflammatory response.

Inappropriate activation of this pathway can result from genetic mutations or factors such as mitochondrial dysfunction, leading to diseases characterised by excessive inflammation.

Novartis immunology research global head Richard Siegel said: “The acquisition of IFM Due represents the culmination of a highly productive, four-year preclinical collaboration between Novartis and IFM to develop novel small-molecule STING inhibitors with the potential to treat a spectrum of inflammatory diseases.

“We are excited to advance IFM Due’s STING programme and leverage our deep expertise in inflammation science to bring forward transformative medicines that address major unmet patient needs.”

Uncover your next opportunity with expert reports

Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.

Newsletters by sectors

close

Sign up to the newsletter: In Brief

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close